Methylation markers

A potential force driving cancer diagnostics forward

Surabhi Khandige, Vikram V. Shanbhogue, Sanjiban Chakrabarty, Satyamoorthy Kapettu

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Epigenetics, transcending genetics, genomics, and molecular biology, is now poised to be the avant-garde beacon of biological science. The rise of DNA methylation studies marks a new dawn in the field of epigenetics, which only a few decades ago was largely underestimated, but is now a dynamic area of research challenging and revising traditional paradigms of gene expression and behavior. Cancer research enjoys a major share of this attention to DNA methylation and it has been widely accepted for some time now that cancer is as much an epigenetic phenomenon as it is genetic. Epigenetic lesions and perturbations are acquired during the life of an individual and accumulate with aging and represent the flip side of the same coin that bears genetic mutations. Both events, either individually or in cooperation, result in the development and progression of cancer. Epigenetic research and the hunt for strong methylation markers has been ably mitigated by new and improved high throughput technology that has improved the efficacy and enabled the rapid progress of biomarker evaluation and validation. This review looks into some of the recent strides in biomarker research dealing exclusively with methylation markers and the potential key they may hold to the resilient door shut tight on cancer diagnostics and treatment.

Original languageEnglish
Pages (from-to)105-110
Number of pages6
JournalOncology Research
Volume19
Issue number3-4
DOIs
Publication statusPublished - 2011

Fingerprint

Epigenomics
Methylation
DNA Methylation
Neoplasms
Research
Biomarkers
Numismatics
Biological Science Disciplines
Genomics
Molecular Biology
Technology
Gene Expression
Mutation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{e1e2a2a124e048a6953a509c9693dadc,
title = "Methylation markers: A potential force driving cancer diagnostics forward",
abstract = "Epigenetics, transcending genetics, genomics, and molecular biology, is now poised to be the avant-garde beacon of biological science. The rise of DNA methylation studies marks a new dawn in the field of epigenetics, which only a few decades ago was largely underestimated, but is now a dynamic area of research challenging and revising traditional paradigms of gene expression and behavior. Cancer research enjoys a major share of this attention to DNA methylation and it has been widely accepted for some time now that cancer is as much an epigenetic phenomenon as it is genetic. Epigenetic lesions and perturbations are acquired during the life of an individual and accumulate with aging and represent the flip side of the same coin that bears genetic mutations. Both events, either individually or in cooperation, result in the development and progression of cancer. Epigenetic research and the hunt for strong methylation markers has been ably mitigated by new and improved high throughput technology that has improved the efficacy and enabled the rapid progress of biomarker evaluation and validation. This review looks into some of the recent strides in biomarker research dealing exclusively with methylation markers and the potential key they may hold to the resilient door shut tight on cancer diagnostics and treatment.",
author = "Surabhi Khandige and Shanbhogue, {Vikram V.} and Sanjiban Chakrabarty and Satyamoorthy Kapettu",
year = "2011",
doi = "10.3727/096504011X12935427587641",
language = "English",
volume = "19",
pages = "105--110",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "3-4",

}

Methylation markers : A potential force driving cancer diagnostics forward. / Khandige, Surabhi; Shanbhogue, Vikram V.; Chakrabarty, Sanjiban; Kapettu, Satyamoorthy.

In: Oncology Research, Vol. 19, No. 3-4, 2011, p. 105-110.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Methylation markers

T2 - A potential force driving cancer diagnostics forward

AU - Khandige, Surabhi

AU - Shanbhogue, Vikram V.

AU - Chakrabarty, Sanjiban

AU - Kapettu, Satyamoorthy

PY - 2011

Y1 - 2011

N2 - Epigenetics, transcending genetics, genomics, and molecular biology, is now poised to be the avant-garde beacon of biological science. The rise of DNA methylation studies marks a new dawn in the field of epigenetics, which only a few decades ago was largely underestimated, but is now a dynamic area of research challenging and revising traditional paradigms of gene expression and behavior. Cancer research enjoys a major share of this attention to DNA methylation and it has been widely accepted for some time now that cancer is as much an epigenetic phenomenon as it is genetic. Epigenetic lesions and perturbations are acquired during the life of an individual and accumulate with aging and represent the flip side of the same coin that bears genetic mutations. Both events, either individually or in cooperation, result in the development and progression of cancer. Epigenetic research and the hunt for strong methylation markers has been ably mitigated by new and improved high throughput technology that has improved the efficacy and enabled the rapid progress of biomarker evaluation and validation. This review looks into some of the recent strides in biomarker research dealing exclusively with methylation markers and the potential key they may hold to the resilient door shut tight on cancer diagnostics and treatment.

AB - Epigenetics, transcending genetics, genomics, and molecular biology, is now poised to be the avant-garde beacon of biological science. The rise of DNA methylation studies marks a new dawn in the field of epigenetics, which only a few decades ago was largely underestimated, but is now a dynamic area of research challenging and revising traditional paradigms of gene expression and behavior. Cancer research enjoys a major share of this attention to DNA methylation and it has been widely accepted for some time now that cancer is as much an epigenetic phenomenon as it is genetic. Epigenetic lesions and perturbations are acquired during the life of an individual and accumulate with aging and represent the flip side of the same coin that bears genetic mutations. Both events, either individually or in cooperation, result in the development and progression of cancer. Epigenetic research and the hunt for strong methylation markers has been ably mitigated by new and improved high throughput technology that has improved the efficacy and enabled the rapid progress of biomarker evaluation and validation. This review looks into some of the recent strides in biomarker research dealing exclusively with methylation markers and the potential key they may hold to the resilient door shut tight on cancer diagnostics and treatment.

UR - http://www.scopus.com/inward/record.url?scp=79952423163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952423163&partnerID=8YFLogxK

U2 - 10.3727/096504011X12935427587641

DO - 10.3727/096504011X12935427587641

M3 - Review article

VL - 19

SP - 105

EP - 110

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 3-4

ER -